The board said talks with prospective robotics and defence partners have convinced it that the sensor business is worth more ...

Tetratherix says the US Food and Drug Administration has accepted the core of its application to sell Tegenix, its bone ...

CSL has agreed to pay Alentis Therapeutics US$355 million upfront in an exclusive deal to jointly develop and promote ...

Citing the Australian Institute of Health and Welfare, BCAL says 48 per cent of women aged 50 to 74 skip routine breast screening.

Average pay for chief executives of Australia's largest listed health care and biotechnology companies rose for a second consecutive year in 2026, while average pay at the smallest companies fell, ...

Paradigm Biopharmaceuticals has entered voluntary administration. The Melbourne drug developer made the move after an interim ...

The United States Food and Drug Administration has granted Telix Pharmaceuticals Fast Track designation for its BiPASS ...

Syntara has announced it will enlarge its clinical trial of a topical scar treatment. It is adding 10 participants and a new ...

Melbourne cryopreservation company Vitrafy Life Sciences has signed its third partnership with a US civilian blood network.

Dr Chris Bremer has taken charge of Neurizon Therapeutics as the Melbourne company counts down to a critical trial result.

Paradigm Biopharmaceuticals has suffered a setback after an independent monitoring board found that its Phase 3 knee ...

The final visit took place in the United States this week. The company told investors that topline results from the XanaMIA ...